Twist Bioscience
TWST
336 hedge funds and large institutions have $7.85B invested in Twist Bioscience in 2026 Q2 according to their latest regulatory filings, with 90 funds opening new positions, 100 increasing their positions, 101 reducing their positions, and 31 closing their positions.
190% more first-time investments, than exits
New positions opened: 90 | Existing positions closed: 31
160% more call options, than puts
Call options by funds: $38.5M | Put options by funds: $14.8M
115% more capital invested
Capital invested by funds: $3.66B → $7.85B (+$4.2B)
20% more funds holding in top 10
Funds holding in top 10: 5 → 6 (+1)
20% more funds holding
Funds holding: 281 → 336 (+55)
1% less repeat investments, than reductions
Existing positions increased: 100 | Existing positions reduced: 101
2.95% less ownership
Funds ownership: 125.63% → 122.68% (-3%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
T. Rowe Price Associates
Baltimore,
Maryland
|
+$232M |
| 2 |
Fidelity Investments
Boston,
Massachusetts
|
+$183M |
| 3 |
D.E. Shaw & Co
New York
|
+$74.1M |
| 4 |
SIMG
Stephens Investment Management Group
Houston,
Texas
|
+$49.9M |
| 5 |
FCM
Farallon Capital Management
San Francisco,
California
|
+$46.1M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
William Blair Investment Management
Chicago,
Illinois
|
-$201M |
| 2 |
EIG
EdgePoint Investment Group
Toronto,
Ontario, Canada
|
-$186M |
| 3 |
AIM
ARK Investment Management
St. Petersburg,
Florida
|
-$117M |
| 4 |
Artisan Partners
Milwaukee,
Wisconsin
|
-$102M |
| 5 |
SCM
Soleus Capital Management
Greenwich,
Connecticut
|
-$73M |
TWST Hedge Fund Activity: Q2 2026 in Review
336 of the 8,298 institutional investors tracked by Wall St. Rank reported a position in Twist Bioscience (TWST) for Q2 2026, worth a combined $7.85B — up 115% from $3.66B a quarter earlier.
Buyers outnumbered sellers: 90 funds opened new TWST positions and 31 closed out — a net gain of 59 holders — while 100 added to existing stakes and 101 trimmed.
The largest buyer was T. Rowe Price Associates, adding an estimated $232M. The largest seller was William Blair Investment Management, cutting an estimated $201M.
- 336 institutional investors held Twist Bioscience (TWST) as of Q2 2026, up from 281 in Q1 2026.
- Funds reported $7.85B of Twist Bioscience stock for Q2 2026, up 115% quarter-over-quarter.
- 90 funds opened new Twist Bioscience positions in Q2 2026 and 31 closed out, a net change of +59 holders.
- The largest Twist Bioscience buyer in Q2 2026 was T. Rowe Price Associates, an estimated $232M added.
- The largest Twist Bioscience seller in Q2 2026 was William Blair Investment Management, an estimated $201M sold.
Based on aggregated 13F filings for Q2 2026.